Protagonist Therapeutics Reports Granting of Inducement Award
The inducement award consists of an option to purchase 75,000 shares of
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
Protagonist is headquartered in
View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-granting-of-inducement-award-301218385.html
Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email: email@example.com; Brian Korb (investors), Tel: +1 646-378-2923, Email: firstname.lastname@example.org